We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
-6.84%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$23.1B
AUM Growth
-$3.48B
Cap. Flow
-$129M
Cap. Flow %
-0.56%
Top 10 Hldgs %
80.48%
Holding
138
New
11
Increased
23
Reduced
15
Closed
12

Top Buys

Rank Stock Value
1
TLIS
Talis Biomedical Corporation Common Stock
TLIS
+$126M
2
IMCR icon
Immunocore
IMCR
+$112M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$106M
4
TIL icon
Instil Bio
TIL
+$99.9M
5
DSGN icon
Design Therapeutics
DSGN
+$48.5M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$737M
2
KRRO icon
Korro Bio
KRRO
+$31.1M
3
ADPT icon
Adaptive Biotechnologies
ADPT
+$22.5M
4
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$13M
5
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$11.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.81%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANAB icon
76
AnaptysBio
ANAB
$1.71B
$9.21M 0.04%
427,179
– –
ISEE
77
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$8.69M 0.04%
1,406,037
– –
NGM
78
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$8.48M 0.04%
291,801
+185,185
+174% +$5.18M
KRTX
79
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$8.41M 0.04%
69,966
– –
GMDA
80
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$8.39M 0.04%
1,037,226
-511,088
-33% -$4.69M
ASMB icon
81
Assembly Biosciences
ASMB
$700M
$7.09M 0.03%
128,452
– –
CABA icon
82
Cabaletta Bio
CABA
$531M
$7.06M 0.03%
636,363
– –
BLUE
83
DELISTED
bluebird bio
BLUE
$6.84M 0.03%
17,523
– –
MGNX icon
84
MacroGenics
MGNX
$261M
$6.39M 0.03%
200,679
– –
BNR
85
Burning Rock Biotech
BNR
$103M
$5.63M 0.02%
20,913
– –
NEXI
86
DELISTED
NexImmune, Inc. Common Stock
NEXI
$5.61M 0.02%
+11,765
New +$6.4M
SGMO
87
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$5.38M 0.02%
429,063
-428,276
-50% -$5.77M
ORTX
88
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$5.33M 0.02%
73,443
+40,193
+121% +$2.85M
SYRS
89
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$5.16M 0.02%
69,017
– –
ITOS
90
DELISTED
iTeos Therapeutics
ITOS
$5.14M 0.02%
150,346
– –
DNLI icon
91
Denali Therapeutics
DNLI
$3.98B
$5.07M 0.02%
88,738
– –
ALEC icon
92
Alector
ALEC
$264M
$4.82M 0.02%
239,228
– –
EVFM
93
DELISTED
Evofem Biosciences, Inc. Common Stock
EVFM
$4.72M 0.02%
179,807
+152,381
+556% +$6.93M
REPL icon
94
Replimune Group
REPL
$1.39B
$4.68M 0.02%
153,512
– –
TVTX icon
95
Travere Therapeutics
TVTX
$6.19B
$4.67M 0.02%
+186,915
New +$5.16M
SRPT icon
96
Sarepta Therapeutics
SRPT
$1.98B
$4.38M 0.02%
+58,700
New +$5.42M
PASG icon
97
Passage Bio
PASG
$14.3M
$4.11M 0.02%
11,768
– –
HRMY icon
98
Harmony Biosciences
HRMY
$2.22B
$4.08M 0.02%
123,600
-56,400
-31% -$1.98M
TCRR
99
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$3.9M 0.02%
176,461
+65,573
+59% +$1.79M
TCDA
100
DELISTED
Tricida, Inc. Common Stock
TCDA
$3.86M 0.02%
729,300
+100,000
+16% +$628K
2 3
4
5 6

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q1 2021 Portfolio in Review

As of Q1 2021, Julian Baker held 138 positions worth $23.1B, down 13% from $26.5B the previous quarter. Its ten largest holdings account for 80% of the portfolio.

Julian Baker's Q1 2021 filing shows 11 new, 23 increased, 15 reduced and 12 closed positions. Its largest new stake was Talis Biomedical Corporation Common Stock: 504,989 shares worth $97.3M. The largest sale was Alexion Pharmaceuticals, an estimated $737M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials.

  • Julian Baker's largest Q1 2021 buy was Talis Biomedical Corporation Common Stock: 504,989 shares worth $97.3M.
  • Julian Baker added most to Global Blood Therapeutics, Inc. in Q1 2021, an estimated $106M increase.
  • Julian Baker's biggest Q1 2021 reduction was Alexion Pharmaceuticals, cutting an estimated $737M.
  • Julian Baker fully exited Adaptive Biotechnologies in Q1 2021, selling an estimated $22.5M.
  • Julian Baker's ten largest holdings make up 80% of its $23.1B portfolio in Q1 2021.
  • Julian Baker opened 11 new positions and closed 12 in Q1 2021.
  • Julian Baker's portfolio value fell 13% quarter-over-quarter to $23.1B.

Based on Baker Bros. Advisors's 13F filing for Q1 2021, filed 17 May 2021.